STAA

STAAR Surgical Company (STAA)
Healthcare • Medical Instruments & Supplies • $23.47 • MCap: 1,176,879,232 🌐
https://www.staar.com • STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Buy Decision Core
Total Score
57
Business Quality
15
Financial Strength
18
Growth Outlook
5
Momentum
1
Price Action
Current
23.47
52W High
33.34
52W Low
16.10
Above 50DMA
25.08 (-6.41%)
Above 200DMA
24.04 (-2.36%)
Relative Strength
Relative Strength
-0.09
RS 3M
-0.22
RS 6M
0.27
RS 9M
-0.11
RS 12M
-0.15
Fundamentals
Revenue Growth
1.11%
Earnings Growth
0%
ROE
0.01%
ROA
0.06%
Valuation
PE (Fwd)
22.93
PEG
0.76
P/B
3.22
Upside
18.88%
Risk
Beta
1.22
Short %
0.18
Risk Score
6.00
Analyst
Rating
none
Target
27.90
Beta
1.22
Analysts
0


Total Score
57
Upside
18.88%
Relative Strength
-0.09
Beta
1.22
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Analyst upside exceeds 15%
Key Risks
  • Weak long-term relative strength
Score Breakdown
Business
15
Financial
18
Growth
5
Valuation
13
Risk
2
Momentum
1
Technical
52W High: 33.34
52W Low: 16.10
Above 50DMA: -6.41%
Above 200DMA: -2.36%
Valuation
Forward PE: 22.93
PEG: 0.76
P/B: 3.22
Upside: 18.88%
Risk
Beta: 1.22
Short Float: 0.18%
ROE: 0.01%
ROA: 0.06%